Abstract:Abstract Introduction Optimal therapeutic cancer discovery pipelines rely on high throughput, reproducibility and minimal bias for candidate discovery and clinical trials. Acute Myeloid Leukemia (AML) cell-based assays, combining flow cytometry (FCM) immunophenotyping with genomic sequencing, provide comprehensive characterization. However, sequential manual gating by expert flow analysts has been shown to have interlaboratory variation, weaknesses with higher dimensional feature spaces due to increased fluorescent channels, and limited scalability for throughput due to the necessary expert interpretation. Automated analysis of Flow Cytometry Standard (FCS) data using a combination of unsupervised and supervised algorithms that combine quality control, gating and clustering strategies offers a more scalable and sustainable option. Given these established breakthroughs, we investigated the use of these informatic tools, combined with sequencing data, to create a therapeutic discovery platform. Methods Peripheral blood and bone marrow samples with abnormal myeloid population and normal controls were exposed to multiple chemotherapeutic small molecules at varying concentrations. Samples were flow cytometrically evaluated with an 8-color tube of antibodies targeting various antigens allowing for apoptosis, viability and blast characterization using standardized lab protocols with a flow cytometer, followed by hematopathologist review. Furthermore, the samples underwent molecular sequencing and annotation with the MyAML® assay to interpret results in the context of AML molecular classification. The computational pipeline utilized Bioconductor version 3.11 open-source packages for quality control, Logicle transformation, apoptosis and viability analyses utilizing a supervised gating strategy. Once viability was established, a Self-Organizing Map (unsupervised dimensionality reduction) algorithm was used to cluster cells into different cell populations. Moreover, a neural network utilizing TensorFlow combined with the API, Keras, was used to detect cell populations from these clusters. The neural network classifier was trained, validated and tested on these clusters compared to expert interpretation. Results Six bone marrow and three peripheral blood samples with the appropriate controls were evaluated via the discovery pipeline. Each sample was exposed to various chemotherapeutic molecules for a total of 203 samples for the pipeline with 50,000 cells per sample. Sequencing demonstrated these samples reflected various European LeukemiaNet (ELN) molecular risk categories. The correlation between the total viable cells in 59 samples as determined by manual and automated gating processes was 98% (r 2=0.98) (Figure 1a). Heatmaps were generated for data visualization of therapeutic efficacy using this viable cell data as demonstrated in one example, Figure 1b, which was consistent with biological hypotheses. Beyond total cell viability detection, cell populations were determined. The validation and test accuracy of our lymphocyte classification model were both 99%, and F1 statistic for model's testing performance was 0.98. Figure 2a displays the ROC curve. The classification of lymphocyte cell population using our combined unsupervised learning/neural network approach for 59 samples had a correlation of 97% (r 2=0.97) (Figure 2b). Conclusions Based on a preliminary comparison with manual gating by an expert flow analyst, we show an automated scalable protocol gives comparable results; therefore, it would be an appropriate alternative to use to screen multiple cells for downstream therapeutic analysis with increased throughput for both cell viability and cell population identification. Figure 1 Figure 1. Disclosures Patay: Invivoscribe: Current Employment, Current holder of stock options in a privately-held company. Zlotnicki: Invivoscribe: Current Employment. Shah: Invivoscribe: Current Employment, Current holder of stock options in a privately-held company. Apilado: Invivoscribe: Current Employment. Andrews: Invivoscribe: Current Employment, Current holder of stock options in a privately-held company.

Abstract 7434: Deployment of a visualization tool directly linked to the CellEngine cytometry analysis software to accelerate analysis of complex cytometry data sets in the context of ongoing clinical trials

Abstract LB252: iCellSight: An interactive tool for analyzing and visualizing in-situ high-plex cellular protein data

Abstract 6202: Integrating public single-cell transcriptomics and patient profiles to guide clinical development

Abstract 4961: Large-scale CyTOF data modeling of leukemia patient cohorts

Abstract 6444: Assessing cytotoxic T cell responses to immune checkpoint inhibitors in murine and human tumor samples using metabolic imaging

Abstract 2390: Longitudinal assessment of circulating tumor DNA in patients with advanced colorectal cancer: A proposed general statistical framework and visualization tool

Abstract 993: Comprehensive immunophenotypic strategies to enable equity in remote settings for improved cancer prognosis

Abstract 6424: A patient centric full spectrum flow cytometry assay for comprehensive phenotyping of CAR T cells in clinical trials

Abstract 2069: High content imaging without sacrificing coverage, resolution or speed: Functional validation through multiple assays

Abstract 77: Real-time multiparametric assessment of immune cell-mediated cytotoxicity

Abstract 5497: Towards a drag and drop spatial biology workflow: Introducing sample reinterrogation as a conduit for the progressive development and on-line analysis of high parameter spatial biology data

Abstract 5157: Development and evaluation of a high-throughput method for rapid detection of surface antigen expression in fixed cells

Abstract 1543: 40-color spectral flow cytometry for comprehensive immunophenotyping of murine cancers

Abstract A025: Novel workflow for characterizing T-cell functional heterogeneity in response to checkpoint inhibitors

Abstract IA020: AI-powered tool for rapid & reliable bladder cancer screening and surveillance: multicenter validation efforts

Abstract 5362: AI-enabled novel workflow to evaluate T-cell activity in vitro using 3D spheroid models

Abstract 4169: A deep learning approach to guide acquisition region selection for imaging mass cytometry

Machine Learning Algorithms Accelerate Throughput of a Flow - Sequencing Cell Based Assay for an Acute Myeloid Leukemia (AML) Therapeutic Discovery Platform

Abstract 1880: High throughput screening of 30 PDX cell lines in a 3D ECM hydrogel platform, incorporating tumor, stroma and immune components to demonstrate simultaneous investigation of multiple anti-tumor modalities

Cell2Cell: Explorative Cell Interaction Analysis in Multi-Volumetric Tissue Data

Abstract 5383: Dexter࣪ microfluidic platform spatially resolves antigen presentation and T cell functions in microdroplets and deciphers dynamic tumor-immune interaction network